Resources

2 Resources for

dan rosenblum

Why Sales Estimates for Dendreon's Provenge Are Too Low: Dan Rosenblum submits: After the initial excitement caused by the Phase 3 IMPACT study of Dendreon's DNDN Provenge for the treatment of metastatic prostate cancer has begun to fade along with the stock price, it is time to consider just how big a drug Provenge can become. ...; Tags: Biotech, Dan Rosenblum, Dendreon Corp.; External links 2009-05-18
Expect Targacept to Move Higher: Dan Rosenblum submits: Having seen small biotech stocks Dov Pharma and Interneuron to name two that showed promising Phase 2 results in treatments for depression which ended up failing after the drugs advanced into Phase 3, I was somewhat skeptical of Targacept's TRGT rapid rise from $4...; Tags: Biotech, Dan Rosenblum, Targacept Inc.; External links 2009-10-21

Will Dendreon's Provenge Benefit From Off-Label Use?: Now that Dendreon's successful Phase 3 trial results for Provenge are in -- let the speculation begin! Dan Rosenblum over at Seeking Alpha thinks potential sales of the prostate cancer drug are being understimated because analysts fail to take into acount off-label use of the drug. by Jim Edwards; Tags: Sales Strategy, Sales Force Management, Sales, Jim Edwards; Blog posts 2009-05-19